MedTrace Logo

Post-Marketing Surveillance for Crohn's Disease Participants Treated With Stelara (Ustekinumab)

NCT03942120 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 685

Last updated 2025-04-27

No results posted yet for this study

Summary

The purpose of post-marketing surveillance (PMS) is to assess the safety and effectiveness of ustekinumab (Stelara) for Crohn's disease participants under real world clinical practice.

Conditions

  • Crohn Disease

Interventions

DRUG

Ustekinumab

Participants treated with ustekinumab under real world clinical practice will be observed in this study. No study drug will be administered as a part of this study.

Sponsors & Collaborators

  • Janssen Korea, Ltd., Korea

    lead INDUSTRY

Principal Investigators

  • Janssen Korea, Ltd., Korea Clinical Trial · Janssen Korea, Ltd., Korea

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-08
Primary Completion
2022-01-14
Completion
2022-01-14
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03942120 on ClinicalTrials.gov